Tirzepatide vs Semaglutide: Which GLP-1 Wins for Weight Loss?
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-06
Two of the most-prescribed metabolic drugs, compared on trial results, dosing, side effects, and cost
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist; semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist. In the SURMOUNT and STEP trial programs, tirzepatide produced greater average weight loss than semaglutide, and a 2024 head-to-head trial (SURMOUNT-5) confirmed tirzepatide's edge — but semaglutide has the longer cardiovascular-outcomes track record and often costs less.
This article is for informational purposes only and is not medical advice. Consult a physician before starting, stopping, or switching any prescription medication.
Tirzepatide and semaglutide are the two active ingredients behind the biggest names in metabolic medicine. Semaglutide is sold as Ozempic (type 2 diabetes) and Wegovy (weight management). Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (weight management). The core difference is mechanism: semaglutide activates one incretin receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1). That extra receptor is the main reason tirzepatide edges out semaglutide on average weight loss in trials. For the brand-specific breakdowns, see our Ozempic vs Mounjaro and Wegovy vs Zepbound comparisons.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Tirzepatide vs Semaglutide at a Glance
Tirzepatide activates two incretin receptors while semaglutide activates one, which is the mechanistic reason tirzepatide leads on average weight loss. The table below compares the two drugs on the dimensions that matter to patients and prescribers.| Dimension | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | Single GLP-1 receptor agonist |
| Brand names | Mounjaro (diabetes), Zepbound (weight) | Ozempic (diabetes), Wegovy (weight), Rybelsus (oral) |
| Avg. weight loss (trials) | ~20-22% at highest dose (SURMOUNT-1) | ~15% at highest dose (STEP-1) |
| Head-to-head result | Greater weight loss in SURMOUNT-5 (2024) | Less weight loss than tirzepatide in the same trial |
| Dosing | Weekly injection; 2.5-15 mg | Weekly injection; 0.25-2.4 mg (Wegovy) / oral Rybelsus daily |
| Cardiovascular outcome data | SURPASS-CVOT reported 2025; newer evidence base | Established (SUSTAIN-6, SELECT) — longer track record |
| List price (weight-loss brand) | Zepbound ~$1,060/mo list | Wegovy ~$1,350/mo list |
| Main side effects | Both: nausea, diarrhea, constipation, vomiting (worst during titration) | |
Which Produces More Weight Loss?
Tirzepatide produces more weight loss on average than semaglutide. In the SURMOUNT-1 trial, adults without diabetes lost about 20-22% of body weight on the highest tirzepatide dose. In the STEP-1 trial, semaglutide (Wegovy) produced about 15%. These were separate trials, so the fairest comparison is SURMOUNT-5, a 2024 head-to-head study in which tirzepatide led to significantly greater weight loss than semaglutide over 72 weeks.
The gap is real but not enormous for every person. Individual response varies widely, and many people reach their goal on semaglutide. Tolerability, insurance coverage, and cost often matter more than the average trial difference.
Side Effects: How They Compare
Both drugs share the same core side-effect profile because they act on overlapping gut-hormone pathways. The most common effects are nausea, diarrhea, vomiting, and constipation, and they are worst during dose escalation. Slower titration usually reduces them.
Because tirzepatide also activates the GIP receptor, its side-effect pattern is not identical, but head-to-head data has not shown it to be meaningfully harder to tolerate than semaglutide for most people. Rare but serious risks (pancreatitis, gallbladder issues, and a boxed warning for medullary thyroid cancer risk seen in rodents) apply to both classes and should be reviewed with a prescriber.
Cost, Access, and Insurance
Cost and coverage often decide the choice more than efficacy does. Zepbound's list price is generally lower than Wegovy's, but the price you actually pay depends on insurance, manufacturer savings cards, and whether the drug is covered for your diagnosis. Insurers frequently cover the diabetes brands (Ozempic, Mounjaro) for type 2 diabetes but deny the weight-loss brands (Wegovy, Zepbound) for obesity.
If neither is affordable, review lower-cost paths in our Ozempic alternatives roundup — metformin, compounded options through a licensed pharmacy, and lifestyle-first insulin-resistance care.
The Bottom Line: Which Should You Consider?
Choose based on your priority, not just the trial averages:
- Maximum weight loss: tirzepatide has the edge in head-to-head data.
- Longest cardiovascular track record: semaglutide has more years of outcome data behind it.
- Lower list price: the tirzepatide weight-loss brand (Zepbound) generally lists below Wegovy, but check your own coverage.
- An oral option: semaglutide is available as a daily pill (Rybelsus); tirzepatide is injection-only.
The best choice is the one your prescriber and insurance make accessible and that you can tolerate. Take the free assessment to see whether appetite, insulin resistance, or another metabolic factor should shape your plan before you compare specific drugs.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For weight loss, tirzepatide produces greater average results in trials, including the 2024 SURMOUNT-5 head-to-head study. But "better" depends on your goal: semaglutide has a longer cardiovascular-outcomes record, is available as a pill (Rybelsus), and may be more affordable depending on your insurance. Neither is universally better for everyone.
Are tirzepatide and semaglutide the same drug?
No. They are different molecules. Semaglutide activates one incretin receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). Semaglutide is sold as Ozempic, Wegovy, and Rybelsus; tirzepatide is sold as Mounjaro and Zepbound. The dual mechanism is the main reason tirzepatide tends to produce more weight loss.
Can you switch from semaglutide to tirzepatide?
Switching is possible and common, but it requires a new titration (dose-escalation) schedule for tirzepatide rather than matching your old semaglutide dose. The two drugs are not interchangeable at the injection level. Any switch should be planned with a prescriber who sets an appropriate starting dose based on your current tolerance.
Which has fewer side effects, tirzepatide or semaglutide?
Both share the same core gastrointestinal side effects — nausea, diarrhea, vomiting, and constipation — most pronounced during dose escalation. Head-to-head data has not shown a large tolerability difference for most people. Slower titration reduces side effects with either drug.
Is tirzepatide or semaglutide cheaper?
The tirzepatide weight-loss brand (Zepbound) generally lists below the semaglutide weight-loss brand (Wegovy), but your actual cost depends on insurance coverage, manufacturer savings cards, and your diagnosis. Diabetes brands (Ozempic, Mounjaro) are often covered while weight-loss brands are frequently denied for obesity.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
What Is Insulin Resistance? Causes, Symptoms & How to Reverse It
What insulin resistance is, how to test for it, and how to reverse it.
-
Hyperinsulinemia
Chronically high insulin: symptoms, causes, how it differs from insulin resistance, and how to reverse it.
-
Metabolic Syndrome — Diagnosis, Risks, and Treatment
The five diagnostic criteria and what they mean for your health.
-
Insulin Resistance Symptoms: 12 Warning Signs
12 clinical warning signs, from acanthosis nigricans to post-meal fatigue.
-
Blood Sugar Crash: Why It Happens and How to Stop It
Reactive hypoglycemia: causes, symptoms, and how to stabilize glucose.
-
Glucose Spikes After Eating: Causes and What to Do
Why blood sugar spikes after eating and what to do about it.
-
Fatigue After Eating: Why Food Makes You Tired
Post-meal fatigue explained — insulin, glucose, and the gut-brain axis.
-
Hypoglycemia Symptoms: Low Blood Sugar Warning Signs
Low blood sugar warning signs and when to seek medical attention.
-
How to Reverse Insulin Resistance Naturally
Evidence-based dietary and lifestyle interventions (3-16 week timeline).
-
Slow Metabolism: Myths, Causes, and What Actually Works
Why metabolism slows, what's myth vs reality, and what the evidence says.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.